Listeria monocytogenes Cancer Vaccines: Bridging Innate and Adaptive Immunity | Zendy

Zachary Morrow | Zendy; Zachary M. Powers | Zendy; JohnDemian Sauer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Listeria monocytogenes Cancer Vaccines: Bridging Innate and Adaptive Immunity

Author(s) -

Zachary Morrow,

Zachary M. Powers,

JohnDemian Sauer

Publication year - 2019

Publication title -

current clinical microbiology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.657

H-Index - 16

ISSN - 2196-5471

DOI - 10.1007/s40588-019-00133-4

Subject(s) - immune system , innate immune system , listeria monocytogenes , acquired immune system , immunology , biology , immunity , immunotherapy , priming (agriculture) , cancer immunotherapy , cancer , t cell , bacteria , genetics , germination , botany

Immunotherapy has emerged as a promising cancer treatment, however success in only select clinical indications underscores the need for novel approaches. Recently Listeria monocytogenes- based vaccines have been developed to drive tumor specific T-cell responses. Here, we discuss recent preclinical studies using L. monocytogenes vaccines, innate immune pathways that influence T-cell priming, and new vaccine strategies in clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research